Latest Nanoform News & Updates

See the latest news and media coverage for Nanoform. We track all announcements, press releases, and industry mentions in real time, all in one place.

Nanoform

Nanotechnology drug particle engineering services provider

nanoform.com

Headquarters: Helsinki, Finland
Founded year: 2015
Company type: Public company
Number of employees: 110–200
Industry: Medical Equipment, Supplies & Distribution

Last updated September 2

Latest news about Nanoform

In short: Nanoform reported Q2 growth, an EU filing delay, UK advice, and a first biologics deal

Company announcements

September 2 Nanoform

Nanoform highlights H1 achievements and outlines 2026 priorities

The company achieved record first-quarter revenues, secured a biologics exclusivity deal, and plans strategic manufacturing collaborations ahead of its target regulatory filing.

August 20 Nanoform

Nanoform reports Q2 2026 financials and regulatory progress

Revenue grew 33% while operating costs fell significantly. The company initiated sterile GMP manufacturing discussions and received positive UK MHRA feedback for nanoenzalutamide.

May 19 Nanoform

Nanoform reports record Q1 revenue and gross margin

Revenue grew 45% to EUR 1.3m, gross margin 94%, and first biologics exclusivity deal signed.

March 30 Nanoform

Nanoform announces delay in nanoenzalutamide MAA submission

Feedback from European scientific advice meeting requires evaluating alternative regulatory pathways, postponing the May 2026 filing. Updated timelines will follow.

Media coverage

August 19 Kauppalehti

Nanoformin result fell short of expectations

Revenue fell short of analysts' forecasts. According to Factset's forecast, the company's revenue was expected to rise to 1.1 million euros. Earnings per share were -0.04 euros, compared to -0.07 euros a year ago. The result...

August 4 Kauppalehti

Good news for Nanoform from Great Britain

The result of the UK medicines regulator's advice was that a hybrid application procedure could potentially be used in the marketing authorisation application for nanoenzalutamide.

July 22 Yahoo Finance

Nanoform Finland Oyj (NANOFH.HE) Q1 FY2026 earnings call transcript

Earnings call Nanoform delivered record Q1 2026 revenue and gross margin, with income exceeding €1.5M for a second consecutive quarter and a 45% average annual...

May 31 Kauppalehti

The 'Pharma Tesla' of the Helsinki Stock Exchange got a blockbuster deal - CEO: Huge news

Medical technology company Nanoform signed an agreement with a US company. The good news is overshadowed by the sufficiency of funding and the delay in the company's drug marketing authorization application. "You don't have to wait long," the CFO says ...

Never miss news about Nanoform

Track Nanoform and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Nanoform competitors & trending companies

Browse news for competitors to Nanoform and other trending companies.